Sign in3 stories
Study '306' enrollment is complete with topline data due in the first half of 2027, while the company reported $819.9 million in cash as of June 30, 2026.
SEC filing
The New Haven biopharma's registration statement covers shares tied to a May 2026 private placement and pre-IPO preferred stock rounds, with no proceeds going to the company from most sales.
SEC filing
Study '207' showed hair count gains and high patient-reported improvement rates at Month 6, ahead of a Phase 2/3 readout expected in 1H 2027.
SEC filing